InvestorsHub Logo
Followers 48
Posts 5518
Boards Moderated 0
Alias Born 09/04/2009

Re: wmjenkins3938 post# 9755

Tuesday, 07/02/2013 11:32:42 PM

Tuesday, July 02, 2013 11:32:42 PM

Post# of 426499
If FDA decides to wait for the outcome study before approving V for ANCHOR, it will send the wrong message to the medical community. Lovaza would continue to be prescribed off-label, causing more AFIB and increased LDL for at-risk patients. Why would FDA want that to happen? Unless it's totally corrupt and in bed with BP like GSK.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News